FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011102961> ?p ?o ?g. }

• W2011102961 endingPage "903" @default.
• W2011102961 startingPage "893" @default.
• W2011102961 abstract "Cyclooxygenase-2 (COX-2) is the rate-limiting enzyme in prostanoid biosynthesis and is involved in tumor progression. We investigated expression of COX-1 and COX-2 in cell lines and tumors from ovarian carcinomas. Expression of COX-2 mRNA and protein was detectable in three of five ovarian carcinoma cell lines and was inducible by interleukin-1beta or phorbolester in a subset of cell lines. Prostaglandin E(2) (PGE(2)) production could be inhibited by the selective COX-2 inhibitor NS-398. In malignant ascites of ovarian carcinomas significantly increased levels of PGE(2) were found compared to other carcinomas or nonmalignant ascites (P = 0.03). We investigated expression of COX-2 by immunohistochemistry in 117 ovarian surface epithelial tumors. Expression of COX-2 was detected in 42% of 86 ovarian carcinomas and in 37% of 19 low malignant potential tumors, but not in 12 cystadenomas or 2 normal ovaries. Expression of COX-1 was detected by immunohistochemistry in 75% of 75 invasive ovarian carcinomas and in 75% of 16 low malignant potential tumors, whereas 2 samples from normal ovaries and 8 cystadenomas were positive for COX-1. In univariate survival analysis of invasive carcinomas, expression of COX-2 was associated with a significantly reduced median survival time (log rank test, P = 0.04). For patients younger than 60 years of age, this association was even more significant (P < 0.004). In contrast, expression of COX-1 was no prognostic parameter (P = 0.89). There was no significant correlation between COX-2 or COX-1 expression and other clinicopathological markers. In multivariate analysis expression of COX-2 was an independent prognostic factor for poor survival (relative risk, 2.74; 95% CI, 1.38 to 5.47). Our data indicate that COX-2 expression is an independent prognostic factor in ovarian carcinoma. Based on the results of this study, it would be interesting to investigate whether ovarian carcinoma patients with tumors positive for COX-2 would benefit from treatment with selective COX-2 inhibitors." @default.
• W2011102961 created "2016-06-24" @default.
• W2011102961 creator A5016995466 @default.
• W2011102961 creator A5024164988 @default.
• W2011102961 creator A5033698551 @default.
• W2011102961 creator A5037184306 @default.
• W2011102961 creator A5051267900 @default.
• W2011102961 creator A5055474704 @default.
• W2011102961 creator A5073557455 @default.
• W2011102961 creator A5082076726 @default.
• W2011102961 creator A5085663844 @default.
• W2011102961 creator A5086449500 @default.
• W2011102961 date "2002-03-01" @default.
• W2011102961 modified "2023-10-16" @default.
• W2011102961 title "Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma" @default.
• W2011102961 cites W1502767888 @default.
• W2011102961 cites W1505131392 @default.
• W2011102961 cites W1506887248 @default.
• W2011102961 cites W1525556816 @default.
• W2011102961 cites W1647640400 @default.
• W2011102961 cites W1685016018 @default.
• W2011102961 cites W1766737321 @default.
• W2011102961 cites W1800050944 @default.
• W2011102961 cites W1815431626 @default.
• W2011102961 cites W1840245667 @default.
• W2011102961 cites W1876325581 @default.
• W2011102961 cites W1966368804 @default.
• W2011102961 cites W1973628488 @default.
• W2011102961 cites W1975528763 @default.
• W2011102961 cites W1978052764 @default.
• W2011102961 cites W1985844039 @default.
• W2011102961 cites W2002985468 @default.
• W2011102961 cites W2003535209 @default.
• W2011102961 cites W2009789140 @default.
• W2011102961 cites W2014363436 @default.
• W2011102961 cites W2040040765 @default.
• W2011102961 cites W2040745635 @default.
• W2011102961 cites W2042207719 @default.
• W2011102961 cites W2043707891 @default.
• W2011102961 cites W2050888137 @default.
• W2011102961 cites W2051686420 @default.
• W2011102961 cites W2068806248 @default.
• W2011102961 cites W2069319974 @default.
• W2011102961 cites W2074196470 @default.
• W2011102961 cites W2075908019 @default.
• W2011102961 cites W2078333049 @default.
• W2011102961 cites W2084080959 @default.
• W2011102961 cites W2085052924 @default.
• W2011102961 cites W2085680573 @default.
• W2011102961 cites W2097997344 @default.
• W2011102961 cites W2115522061 @default.
• W2011102961 cites W2117580825 @default.
• W2011102961 cites W2119504955 @default.
• W2011102961 cites W2123927174 @default.
• W2011102961 cites W2124754870 @default.
• W2011102961 cites W2127558096 @default.
• W2011102961 cites W2133620160 @default.
• W2011102961 cites W2136789423 @default.
• W2011102961 cites W2145519419 @default.
• W2011102961 cites W2147012732 @default.
• W2011102961 cites W2161515819 @default.
• W2011102961 cites W2189139307 @default.
• W2011102961 cites W2255046153 @default.
• W2011102961 cites W2330709704 @default.
• W2011102961 cites W4211149743 @default.
• W2011102961 doi "https://doi.org/10.1016/s0002-9440(10)64912-7" @default.
• W2011102961 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1867167" @default.
• W2011102961 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11891188" @default.
• W2011102961 hasPublicationYear "2002" @default.
• W2011102961 type Work @default.
• W2011102961 sameAs 2011102961 @default.
• W2011102961 citedByCount "184" @default.
• W2011102961 countsByYear W20111029612012 @default.
• W2011102961 countsByYear W20111029612013 @default.
• W2011102961 countsByYear W20111029612014 @default.
• W2011102961 countsByYear W20111029612015 @default.
• W2011102961 countsByYear W20111029612016 @default.
• W2011102961 countsByYear W20111029612017 @default.
• W2011102961 countsByYear W20111029612018 @default.
• W2011102961 countsByYear W20111029612019 @default.
• W2011102961 countsByYear W20111029612020 @default.
• W2011102961 countsByYear W20111029612021 @default.
• W2011102961 crossrefType "journal-article" @default.
• W2011102961 hasAuthorship W2011102961A5016995466 @default.
• W2011102961 hasAuthorship W2011102961A5024164988 @default.
• W2011102961 hasAuthorship W2011102961A5033698551 @default.
• W2011102961 hasAuthorship W2011102961A5037184306 @default.
• W2011102961 hasAuthorship W2011102961A5051267900 @default.
• W2011102961 hasAuthorship W2011102961A5055474704 @default.
• W2011102961 hasAuthorship W2011102961A5073557455 @default.
• W2011102961 hasAuthorship W2011102961A5082076726 @default.
• W2011102961 hasAuthorship W2011102961A5085663844 @default.
• W2011102961 hasAuthorship W2011102961A5086449500 @default.
• W2011102961 hasBestOaLocation W20111029611 @default.
• W2011102961 hasConcept C121608353 @default.
• W2011102961 hasConcept C126322002 @default.
• W2011102961 hasConcept C142724271 @default.
• W2011102961 hasConcept C181199279 @default.

• next